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Background: To describe the preliminary experience using Micro Vascular Plug (MVP) for treatment of pulmonary
arteriovenous malformations (PAVMs) with small feeding arteries (3 -5 mm) in four patients with Hereditary
Haemorrhagic Telangiectasia (HHT).
Material and methods: One female and three male patients with PAVMs have been treated during 2017. The
mean age was 32.5 years; (range: 20–53). All patients underwent contrast echocardiography and computed
tomography of the chest to establish the diagnosis.
Results: Four patients with PAVMs were treated with embolisation using the MVP-3Q and MVP-5Q micro plugs. All
MVP were placed without complications and with following immediate occlusion of the PAVMs in all three cases. In
one case MVP was placed semi selectively. All cases were with the good clinical outcomes.
Conclusion: MVP is a new detachable embolisation material which is easy to use. Maximal control during the
deployment and immediate occlusion of the target vessels can be achieved.
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Hereditary Haemorrhagic Telangiectasia (HHT) is an
autosomal dominant disease, frequently associated
with arteriovenous malformations in the brain, lungs,
gastrointestinal tract and liver (Faughnan et al., 2011).
Pulmonary arteriovenous malformations (PAVMs) are
anomalous communications between pulmonary arter-
ies and veins and occur in 15–50% of people with
HHT (Faughnan et al., 2011; Kjeldsen et al., 2000).
They have one or more feeding arteries, an aneur-
ismal sac and one or more draining veins; they can
be simple (with one feeding artery) or complex (with
more than one feeding artery).* Correspondence: stevo.duvnjak@rsyd.dk; duvnjak.stevo@gmail.com
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reproduction in any medium, provided you giv
the Creative Commons license, and indicate ifPAVM can be associated with life-threatening compli-
cations, like transient ischemic attack (TIA), stroke,
cerebral access, haemoptysis and haemothorax. Neuro-
logical complications occur via paradoxical embolisation
(Cottin et al., 2004; Cartin-Ceba et al., 2013), while
haemorrhagic pulmonary complications can occur due
to rupture of PAVMs which is very rare, described in
only a few cases (Kundu et al., 2010).
Screening for PAVMs has to be performed at the time
of the initial evaluation for HHT using contrast echocar-
diography (CE) (Parra et al., 2010). CE is considered
positive if there is detection of any bubbles in the left
atrium; positive CE has to be followed by computed
tomography (CT) of the thorax.
PAVMs are usually treated with embolisation to pre-
vent complications (Iqbal et al., 2000, Moussouttas et al.,
2000). Treatment aims to occlude the feeding artery as
close as possible to the sac. Several devices have been
used during the years (balloons, coils, microcoils,is distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
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However, recanalisation of embolized PAVM can occur
in between 5 and 15% (Milic et al., 2005). Microvascular
plug (MVP) is a new tool in the embolisation toolbox. It
is a detachable nitinol skeleton plug, coated with poly-
tetrafluoroethylene (PTFE) (Pellerin et al., 2014). There
are potential advantages of using MVP, such as the abil-
ity to deploy through a microcatheter close to the PAVM
sac with immediate occlusion. Further, the device can be
retracted and replaced, less metal artefact compared to
coils, possibility to prevent device migration and less
probability to have recanalisation because of the PTFE
coating (Boatta et al., 2017).
There are two sizes of MPVs: MPV-3Q used for arter-
ies ≤3 mm or less in size, and MPV-5Q for arteries of
3–5 mm. Both microplugs are designed to be delivered
through microcatheters, MPV-3Q is compatible with
microcatheter of 2.4 Fr (0.021-in. inner lumen diameter),
and MVP-5Q is compatible with 2.8 Fr (0.027-in. inner
lumen diameter).
This preliminary report aims to describe the intrapro-
cedural experience using MVP in the treatment of
PAVM.
Material and methods
Three female and one male (mean age 32,5 years; range:
20–53) with PAVMs diagnosed on CE and CT have been
embolized with MVPs.
Embolization procedure
Odense University hospital is the Danish national centre
for diagnosis and treatment of HHT patients. Patients
with PAVMs are generally treated with embolization if
they have PAVM with ≥3 mm feeding artery, and in
some cases even smaller (Andersen and Kjeldsen, 2012).
The embolizations have been performed in local an-
aesthesia via the right femoral vein through a 7-F sheath.
All PAVM embolizations have been performed in a
bi-plane angio-room (Artis zee biplane, Siemens AG
Erlangen,Germany). 70 UI/per kg of heparin was admin-
istrated in a bolus. No antibiotics were given during the
embolization. 7 Fr 100 cm long ConsierGE guiding cath-
eter (MeritMedical, South Jordan, UT, USA) and co-
axially advanced 5 Fr 125 cm long Bernstein shape
catheter (MeritMedical, South Jordan, UT, USA) was
navigated to the pulmonary artery. The angiography
confirmed the PAVM and automatic vessels measure-
ment using the software (Syngo QVA vascular analysis)
of the feeding artery was performed. Microcatheter ei-
ther 2.4 Fr or 2.8 Fr was advanced coaxially into the
feeding artery as close as possible to the PAVM and
MVP was deployed. The patients were admitted to
the hospital and discharged within 24 h after the
intervention.Follow-up
Clinical and CE follow-up was performed in three cases
and only clinical examination in one case. The mean
follow-up period was 15.5 months.
Ethics
All procedures in the studies involving human partici-
pants were performed according to the ethical standards
of the institutional and national committee. The local
data protection agency approval with the journal num-
ber 17/14191.
Cases presentation
Case 1
A-52-year-old female with HHT. Saturation at rest was
96% and during exercise decreased to 92%. CE con-
firmed a shunt with grade I-II. CT without contrast con-
firmed a simple PAVM in the left lower lobe with a
feeding artery of 3 mm. The left pulmonary artery was
catheterised, and angiography depicted the PAVM
(Fig. 1a, b). The PAVM was first embolised with a de-
tachable coil of 4 mm diameter and 10 cm in length
(Interlock, Boston Scientific Marlborough, MA, USA).
After ten minutes waiting there was still flow thought
the PAVM. It was decided to deploy an MVP-3Q (Re-
verse Medical Corporation, Irvine CA, USA) through a
2.4 Fr microcatheter (Renegade microcatheter, Boston
ScientificMarlborough, MA, USA) with following imme-
diate occlusion (Fig. 2a-c). No complications occurred
during the intervention. The patient was discharged the
following day, and follow-up consists of clinical and CE
control which showed improved oxygenation and no
shunt at CE control six months after embolization.
Case 2
A-19-year-old female with HHT and haemoptysis under-
went three PAVM embolizations previously. The last
embolization was performed in 2009, and the patient
was without complaints. Recently she complained about
shortness of breath and pain during mild exercise. Satur-
ation at rest was 92% and during the exercise decreased
to 89%. CE confirmed a shunt grade I-II. CT without
contrast confirmed two new PAVMs. The right pulmon-
ary artery was catheterized, and angiography depicted
two PAVMs, one in a right upper lobe and one in the
right lower lobe (Fig. 3a, b). Both PAVMs had feeding ar-
teries with a diameter of 3.2 mm. The PAVM in the
lower lobe was embolized with a detachable coil (Inter-
lock, Boston ScientificMarlborough, MA, USA), 6 mm
in diameter and 10 cm long. The PAVM located in the
upper lobe was engaged coaxially with microcatheter 2.8
Fr (Renegade Hi-Flo; Boston ScientificMarlborough,
MA, USA) and primarily embolized with MVP-5Q
(Reverse Medical Corporation, Irvine CA, USA) with
Fig. 2 a After coil deployment, there was still flow in PAVM. b and c An additional MVP-3Q was deployed, and the flow stopped immediately
Fig. 1 a Baseline pulmonary digital subtraction angiography in a 52-year-old woman, affected by HHT, with several small PAVMs. b The biggest
of these was located in the left lower lobe, with a feeding artery of 3 mm
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Fig. 3 a A 19-year-old woman with HHT. Small PAVM with feeding artery 3.2 mm in the right upper lobe. b Previous embolization with coils of
complex PAVM in the same lobe
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cations occurred during the intervention. The patient
was discharged the next day, and follow-up consisted of
clinical and CE control showed improved oxygenation
up to 96% and no shunt at six months CE control.
Case 3
A-32-year-old female with nasal bleeding during two years.
A diagnosis of HHT was established. Oxygen saturation
was 98% without significant changes during exercise. CE
confirmed shunt grade II-III and non-contrast CT showed
two PAVMs, one located in the right lower lobe with feed-
ing artery of 5 mm and the other with feeding artery of
3.3 mm in diameter located in the right upper lobe (Fig. 5).Fig. 4 a Before deployment of MVP-5Q. b After deployment of MVP-5Q, imThe PAVM in the lower lobe was embolized with Amplat-
zer plug IV (St Jude Medical, Minnesota, USA), 8 mm in
diameter. The PAVM in the upper lobe was embolized with
MPV-5Q (Reverse Medical Corporation, Irvine CA, USA)
delivered through a microcatheter 2.8 Fr (Renegade Hi-Flo;
Boston ScientificMarlborough, MA, USA) with following
immediate occlusion of both PAVMs (Fig. 6 a, b). No com-
plications occurred during the deployment. The patient
was discharged the next day, and clinical control and CE
showed no shunt six months after embolization.
Case 4
20-year-old male patient with diagnosed HHT and mul-
tiple PAVMs in both lungs. Embolization of PAVMs inmediate stop of flow
Fig. 5 Non-contrast CT showed a simple PAVM in right upper lobe
with feeding artery of 3, 3 mm in diameter
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outcome. In 2017 CE control showed shunt grade II-III and
CT confirmed two PAVMs in the right lung. The biggest
had a feeding artery of 6 mm and was embolized with
Amplatz plug IV (St Jude Medical, Minnesota, USA), 8 mm
in diameter a few months before the actual intervention
(Fig. 7). The smaller PAVM in the right lower lobe had two
feeding arteries. One feeding artery with a diameter of
3 mm was embolized with a detachable coil 4 mm and
8 cm in length (Interlock, Boston ScientificMarlborough,Fig. 6 Pulmonary angiography before and after embolization of both PAVM
with MVP-5QMA, USA). The other feeding artery with a diameter of
3.4 mm was embolized with MVP-5Q delivered through a
microcatheter 2.8 Fr (Renegade Hi-Flo; Boston Scientific-
Marlborough, MA, USA), but due to highly angulated feed-
ing artery the MVP was displaced a little proximally and
occluded the feeding artery a longer distance to the PAVM
than intended (Fig. 8). No complications occurred, and the
patient was discharged the following day without
symptoms. The patient was asymptomatic at clinical
control 12 months after the embolization, and no CE
was performed during the follow-up. The patient did
not experience any symptoms during the 12 months
follow-up period.
Discussion
This case series described an early experience with the
new embolization material and showed high technical
success and control during the embolization of four
PAVMs. The main advantage of MVP is a possibility to
deploy the plug through the microcatheter, and if the
planning is accurate, only one MVP is needed to achieve
complete occlusion. One important feature of the new
device is that we need straight at least 12 mm long ves-
sel to deploy the MVP precisely. In the case of vessel
tortuosity and sharp take off of the branch vessels, the
deployment can be more challenging. The best results
are achieved when the embolization material is placed
close as possible to PAVM sac and where the distance
between the PAVM sac and embolization material is
under 1 cm, especially in PAVM with small feeding ar-
tery as reported by (Stein et al., 2017). They found the
higher rate of reperfusion of the PAVM in a case of the
proximally placed embolization material. The present
case with difficulties to deploy the microplug close to
the PAVM sac in tortuous anatomy showed the potentials in the right lung. The PAVM in upper lobe was embolized
Fig. 7 Pulmonary angiography before embolization of PAVMs in the right lung with two feeding arteries
Duvnjak et al. CVIR Endovascular  (2018) 1:19 Page 6 of 7limitation of this new device. The possible combinations
of the microcoils and microplug can be a solution in
such environment. However, the further study can con-
firm the value of such an approach.
The present reports in the literature have the same ex-
perience with the MVP (Boatta et al., 2017; Pellerin O
et al., 2014; Conrad et al., 2015).
The possible migration of the device is mentioned as a
complication because of the undersized diameterFig. 8 The PAVM in lower lobe was embolized with detachable coil
and with MVP-5Q(Conrad et al., 2015). We did not have any distal migra-
tion as we followed instruction for use, where the vessels
with a diameter of ≤3 mm should be embolized with
MVP-Q3 and vessels with diameter 3–5 mm should be
embolized with the MVP-5Q. However, in the present
cases report CT control was not performed to evaluate
device migration eventually. Other authors recommend
coils placement additionally in a case of incomplete oc-
clusion or in a case of plug migration (Trerotola S et al.,
2010). The potential challenge with this technique using
the MVP-5Q is that the microcatheter has to be ex-
changed to the 0.021-in. inner lumen to avoid jamming
of the coils when pushing coils thought a 0,027-in. inner
lumen microcatheter. It is very important to avoid or to
reduce manipulation and exchange of the material to
avoid thrombus formation eventually, and air embolism
and pre-interventional planning are very important. The
CT and angiography measurement before advancing the
embolization material is usually sufficient to choose the
appropriate material and avoid too much manipulation.
Conclusion
MVP embolization of PAVMs appears technically feas-
ible, safe, and effective at early follow-up.
Further prospective studies on bigger populations are
required to confirm long-term safety and efficacy of this
promising new embolization material.
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